Tencent takes stake in hemophilia drug company

2024-06-04 08:30:17

Asia Tech Wire (June 4) -- Chinese tech giant Tencent has taken a stake in hemophilia drug company Gensciences Inc.

Gensciences underwent an industrial and commercial change on Monday, adding Tencent Mobility Limited, a subsidiary of Tencent, and an investment unit under Shanghai Zhangjiang Group Co. as its shareholders.

Founded in 2019, Gensciences is a hemophilia innovative drug company, according to the company's website.

The company currently has four innovative drugs in clinical development and registration review.

biotech Tencent

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Tencent Holdings repurchased 3.93 million shares for HK$1.5 billion on January 7
                            2025-01-07

                                    Ireland recorded a 12.8 billion euro fiscal surplus last year due to the "Apple tax" ruling
                            2025-01-07

                                    Ministry of Industry and Information Technology: Promoting technical verification of 10G optical network and artificial intelligence integration
                            2025-01-07

                                    Tencent's major shareholder Prosus reduced its stake in Tencent Holdings from 24.01% to 23.99% on January 6.
                            2025-01-07

                                    U.S. chip stocks rose before the market opened, with Nvidia up 0.6%
                            2025-01-07